FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Inhibrx's Free Cash Flow for the
three
months ended in Mar. 2024 was $-64.17 Mil. Inhibrx's Revenue for the
three
months ended in Mar. 2024 was $0.00 Mil. Therefore, Inhibrx's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.
The historical rank and industry rank for Inhibrx's FCF Margin % or its related term are showing as below:
INBX'
s FCF Margin % Range Over the Past 10 Years
Min: -12456.76 Med: -385.17 Max: -252.73
Current: -12456.76
During the past 7 years, the highest FCF Margin % of Inhibrx was -252.73%. The lowest was -12456.76%. And the median was -385.17%.
INBX's FCF Margin % is ranked worse than 92.25% of 1045
companies
in the Biotechnology industry
Industry Median: -143.92
vs INBX: -12456.76
Inhibrx FCF Margin % Historical Data
The historical data trend for Inhibrx's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Inhibrx's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibrx's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibrx's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Inhibrx's FCF Margin % falls into.
Inhibrx FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Inhibrx's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibrx FCF Margin % Related Terms
Thank you for viewing the detailed overview of Inhibrx's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INBX has been successfully added to your 